California State Teachers Retirement System trimmed its holdings in shares of Immunomedics, Inc. (NASDAQ:IMMU) by 5.6% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 181,089 shares of the biopharmaceutical company’s stock after selling 10,800 shares during the quarter. California State Teachers Retirement System owned 0.16% of Immunomedics worth $1,599,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Raymond James Financial Services Advisors Inc. increased its stake in Immunomedics by 11.4% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 14,400 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 1,473 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in Immunomedics by 2.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 79,520 shares of the biopharmaceutical company’s stock worth $702,000 after purchasing an additional 1,763 shares in the last quarter. State Street Corp increased its stake in Immunomedics by 37.2% during the 2nd quarter. State Street Corp now owns 4,818,847 shares of the biopharmaceutical company’s stock worth $42,549,000 after purchasing an additional 1,305,298 shares in the last quarter. Gotham Asset Management LLC bought a new stake in Immunomedics during the 2nd quarter worth approximately $2,388,000. Finally, DAFNA Capital Management LLC increased its stake in Immunomedics by 152.5% during the 2nd quarter. DAFNA Capital Management LLC now owns 637,700 shares of the biopharmaceutical company’s stock worth $5,631,000 after purchasing an additional 385,126 shares in the last quarter. 61.41% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “California State Teachers Retirement System Lowers Position in Immunomedics, Inc. (IMMU)” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/california-state-teachers-retirement-system-lowers-position-in-immunomedics-inc-immu/1713453.html.

In other news, insider David M. Goldenberg sold 20,000 shares of the stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $12.64, for a total value of $252,800.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Cynthia L. Goldenberg sold 40,000 shares of the stock in a transaction that occurred on Wednesday, August 23rd. The shares were sold at an average price of $9.24, for a total value of $369,600.00. The disclosure for this sale can be found here. Insiders have sold a total of 100,000 shares of company stock valued at $1,051,200 over the last ninety days. Company insiders own 6.60% of the company’s stock.

A number of analysts recently issued reports on the company. Zacks Investment Research cut Immunomedics from a “buy” rating to a “hold” rating in a research note on Wednesday. Jefferies Group LLC increased their target price on Immunomedics from $11.00 to $14.00 and gave the stock a “buy” rating in a research note on Tuesday, September 19th. BidaskClub raised Immunomedics from a “hold” rating to a “buy” rating in a research note on Wednesday, August 23rd. Finally, Cowen and Company reaffirmed an “outperform” rating and set a $15.00 price target on shares of Immunomedics in a research note on Monday, July 24th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $15.33.

Immunomedics, Inc. (IMMU) opened at $11.75 on Friday. Immunomedics, Inc. has a 52 week low of $2.92 and a 52 week high of $14.48. The company has a current ratio of 0.74, a quick ratio of 0.74 and a debt-to-equity ratio of -0.29.

Immunomedics (NASDAQ:IMMU) last issued its quarterly earnings results on Wednesday, August 16th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.13). The firm had revenue of $0.64 million for the quarter, compared to the consensus estimate of $0.75 million. The firm’s quarterly revenue was down 31.2% on a year-over-year basis. During the same period in the prior year, the company earned ($0.17) earnings per share. research analysts expect that Immunomedics, Inc. will post -1.16 earnings per share for the current fiscal year.

Immunomedics Profile

Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Institutional Ownership by Quarter for Immunomedics (NASDAQ:IMMU)

Receive News & Ratings for Immunomedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.